Wire · operational-macro
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
The FDA has accepted a supplemental new drug application for the combination of selinexor and ruxolitinib in treating myelofibrosis, based on the phase 3 SENTRY trial showing significant spleen volume reduction and improved overall survival signals. The review targets a potential first approved combination therapy beyond existing JAK inhibitor monotherapy with a decision expected by June 28, 2027.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now prepare for a new FDA regulatory pathway opening in myelofibrosis with a combination treatment that could reshape treatment standards. Trial success signals an opening to target patients beyond JAK inhibitor monotherapy.
◆ Coverage
1 source · 17 Nov 2026
◆ Related on Wire
◆ Topics